Lingkang Pharmaceutical's wholly-owned subsidiary Hainan Lingkang Pharmaceutical had its Huperzine A for Injection selected in the 34-drug provincial alliance centralized volume-based procurement. This procurement is led by Henan Province, covering 28 provincial-level administrative regions, with a procurement cycle of two years. The selected specification is 0.2 mg, indicated for benign memory impairment and myasthenia gravis. This product is the only injectable freeze-dried powder approved for marketing in China, and its core ingredient Huperzine A is an original drug developed globally. The company stated that the selection is conducive to expanding channels in public hospitals and increasing market share.
Lionco Pharm Grp Co LtdProduct selected in centralized procurement, expanding hospital channels and market share.
